Navigation Links
Positive Clinical Data for TASQ - Active Biotech's Novel Treatment,of Prostate Cancer

LUND, Sweden, March, 9, 2007-Active Biotech (ACTI.ST), today announced new positive clinical data from the Phase Ib study of TASQ, for the treatment of prostate cancer.

By step-wise dose escalation, a safe dose of 1 mg/day of TASQ was achieved, which corresponds to a doubling of the previously reported maximum tolerated dose (MTD) level of 0.5 mg/day. This means that a step-wise intra-patient dose-escalation enables a dose of 1 mg/day to be administered in future clinical trials.

"These new results confirm and reinforce earlier results obtained at a lower dose level. We now have a very complete data set that constitute a solid base to move into Phase II clinical trials", said Sven Andréasson, President and CEO of Active Biotech.

The ongoing 10-week study comprises patients with so called hormone-refractory prostate cancer. This is an advanced stage of prostate cancer where the tumor cells no longer respond to hormone treatment. All patients entering the study had rising serum levels of Prostate Specific Antigen (PSA), which is a surrogate marker for tumor progression.

PSA measurements were recorded and PSA velocity (PSAV) was calculated after 28 days of treatment. Five out of six patients had a >50% decrease in PSA velocity compared to prior treatment. Three of these five patients exhibited a decrease in absolute PSA levels.

The study is being performed at the urological clinics at the University Hospitals in Lund, Malmö and Uppsala, Sweden.

The objective of the TASQ project is to develop a pharmaceutical product that can be administered orally for the long-term treatment of prostate cancer. Phase II studies are scheduled to start during 2007. The Medical Products Agency has approved on the new MTD to be used in the continued clinical program of TASQ.

The pharmaceutical market for prostate cancer is estimated at more than USD 3 billion a year. Prostat
'"/>




Page: 1 2

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis

Post Your Comments:
(Date:11/6/2009)... Nov. 6 The ,Help is He...olina and Georgia throughout the week of November ...and financially-struggling patients access informa...es for free or nearly free. With the nation,s unem...rship for Prescription Assistance (PPA) bus tour i...
(Date:11/6/2009)...v. 6 Derma Sciences, I...vanced wound care products, announced plans to rel...on Monday, November 16, 2009. The Company will hol...esults at 11:00 am EST. Interested parties should ...international), with passcode 81416481 to access t...
(Date:11/6/2009)...PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: ...ping products for minimally disruptive surgical tr...tment of Michael J. Lambert as Executive Vice Pres...ber 9, 2009. The Company also announced several o...hael will be an excellent complement to the NuVasi...
Breaking Medicine Technology:Partnership for Prescription Assistance Prepared to Help Southern Workers Hurt by Recession 2Partnership for Prescription Assistance Prepared to Help Southern Workers Hurt by Recession 3Derma Sciences Announces Date of Its Third Quarter 2009 Earnings Release and Conference Call 2NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 2NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 3NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 4NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 5Distressed Patients Suffer Panic Attacks as UK Medicine Stocks Hit by Shortages Chemist+Druggist Reveals 55019 1Distressed Patients Suffer Panic Attacks as UK Medicine Stocks Hit by Shortages Chemist+Druggist Reveals 55019 2Celling Technologies Sets New Standards With Sophisticated Adult Stem Cell Device 55015 1Celling Technologies Sets New Standards With Sophisticated Adult Stem Cell Device 55015 2Celling Technologies Sets New Standards With Sophisticated Adult Stem Cell Device 55015 3New Sigma Advanced Genetic Engineering Labs Offers Research Community Unique Rodent Models Developed Using Exclusive Gene Editing Technology 13645 1New Sigma Advanced Genetic Engineering Labs Offers Research Community Unique Rodent Models Developed Using Exclusive Gene Editing Technology 13645 2New Sigma Advanced Genetic Engineering Labs Offers Research Community Unique Rodent Models Developed Using Exclusive Gene Editing Technology 13645 3
(Date:11/8/2009)...y of Health holds open house at Victoria campus ,...mber 8, 2009 -- UCW Academy of Health invites anyo...squo;s health care industry to attend their open h..., ,UCW Academy of Health, which offers diplomas i... services, designs its programs to meet the needs ...
(Date:11/8/2009)...-USNewswire/ -- Tonight the House of Representativ...ct, landmark health reform legislation that will e...able, stable and secure health care coverage. The ...rance industry,s worst practices, would extend cov...by $104 billion over ten years. Groups representin...
(Date:11/8/2009)...s Health Network (MHN) urges military veterans to ...inked to exposure to chemicals, atomic agents and ...r is one of those cancers that is two times more p...oked or currently smoke cigarettes. , ...9 -- Men’s Health Network (MHN) kicked-off t...
(Date:11/8/2009)...ispanic health advocates committed to achieving me...TON, Nov. 7 "Tonight th...eard the voice of America,s families by passing th...Senate must deliver, without delay, on the promise...L. Delgado, President and CEO of the National Alli...
(Date:11/8/2009)...-USNewswire/ -- The following was released today b...ecta Nex. ,, Mr. Terry and his associates from...ld-killing by abortion out of any health care bill...eat first step to victory -- a touchdown in the fi... of us. Our rejoicing must be tempered by reality....
Breaking Medicine News(10 mins):Health News:College Invites Public to Explore Career Options in Health Care 2Health News:Democratic National Committee Chairman Tim Kaine Issues Statement Praising the House of Representative's Historic Vote to Pass Health Insurance Reform 2Health News:Democratic National Committee Chairman Tim Kaine Issues Statement Praising the House of Representative's Historic Vote to Pass Health Insurance Reform 3Health News:Veterans' Day Reminder from Men's Health Network: Pay Attention to Bladder Cancer Symptoms and Risk Factors 2Health News:Veterans' Day Reminder from Men's Health Network: Pay Attention to Bladder Cancer Symptoms and Risk Factors 3Health News:National Alliance for Hispanic Health President and CEO Applauds House Action, Calls on Senate to Pass Health Reform in 2009 2
... GlaxoSmithKline (NYSE:,GSK) announced that a ret...hat anti-HIV regimens containing EPZICOM (abacavir...atients regardless of baseline viral loads.,One of...icitabine) in treatment-naive patients with both h...
...ew interventions to control body,s attack on its o...althDay News) -- B cells may be more responsible f...atoid arthritis than initially thought, according ...ys to stop the immune system,s chronic attacks on ...
...Volcano Corporation,(Nasdaq: VOLC ), a provider o...urement (FM) and Optical Coherence Tomography (OCT...reatment of coronary and peripheral vascular,disea... Huennekens, president and chief executive,officer...
...may lead to more effective screening and treatment...me characterized by tumor-like growths and a high ... published by Cell Press in the August 7 issue of ...d related disorders. , Mutations of the common t...
... dedicated breast MRIs to skyrocket over the next ...search Group, WALTHAM, Mass., Aug. 7 According t... Women,s Health Imaging Systems 2008 report,the ma...amma imaging (BSGI) systems -- will grow at a comp...
...7, 2008The American Association of Diabetes Educat...onducted by Harris Interactive highlighting commun...insulin injections and their healthcare providers....y agreed/25 percent somewhat agreed), 14 percent o...
Other Medicine News:Health News:Analysis of Six Clinical Trials Finds EPZICOM(R) Effective in Treatment-Naive HIV Patients With Both High and Low Baseline Viral Loads 2Health News:Analysis of Six Clinical Trials Finds EPZICOM(R) Effective in Treatment-Naive HIV Patients With Both High and Low Baseline Viral Loads 3Health News:Analysis of Six Clinical Trials Finds EPZICOM(R) Effective in Treatment-Naive HIV Patients With Both High and Low Baseline Viral Loads 4Health News:Analysis of Six Clinical Trials Finds EPZICOM(R) Effective in Treatment-Naive HIV Patients With Both High and Low Baseline Viral Loads 5Health News:Analysis of Six Clinical Trials Finds EPZICOM(R) Effective in Treatment-Naive HIV Patients With Both High and Low Baseline Viral Loads 6Health News:Volcano Presentation at Canaccord Adams Conference to be Webcast 2Health News:Beyond PTEN: Alternate genes linked to breast, thyroid and kidney cancer predisposition 2Health News:Adjunct Breast Imaging Market to Increase by Almost 28% per Year Through 2013 2Health News:New survey explores the impact of insulin injections on people with diabetes 2Health News:New survey explores the impact of insulin injections on people with diabetes 3Health News:New survey explores the impact of insulin injections on people with diabetes 4
...ies is a national reference laboratory and a world...development. ARUP offers an extensive test menu of...al and anatomic pathology. Owned by the University...than half of the nation's university teaching hosp...
...ies is a national reference laboratory and a world...development. ARUP offers an extensive test menu of...al and anatomic pathology. Owned by the University...than half of the nation's university teaching hosp...
...ies is a national reference laboratory and a world...development. ARUP offers an extensive test menu of...al and anatomic pathology. Owned by the University...than half of the nation's university teaching hosp...
...ies is a national reference laboratory and a world...development. ARUP offers an extensive test menu of...al and anatomic pathology. Owned by the University...than half of the nation's university teaching hosp...
Medicine Products: